Overview
Searching for cures and therapies for rare diseases is no longer a niche market. Instead, it has become a major sector of biotech. Here are 11 companies that are leading the way.
The rare disease market is booming. Global Market Insights valued it at $265.5 billion in 2026 and projects it will reach $726 billion by 2035. The forces driving that growth are as much about strategy and infrastructure as they are about science.
“Rare disease is no longer a niche; it’s becoming the default operating model for biotech innovation, and the bottleneck has shifted from science to manufacturing and reimbursement, so whoever solves scalable platforms and durable payer models wins the next decade,” says Marc Hedrick, MD, CEO and President of Plus Therapeutics.
Part of what’s changed is the regulatory landscape. Programs like orphan drug designation and accelerated approval have made the path to market more flexible, says Alex Yang, JD, CEO of Polaryx Therapeutics. “More recently, we’ve also seen the FDA emphasize approaches such as leveraging a plausible mechanism of action, natural history data, and biomarker-driven evidence to support development and potential expedited approvals, particularly in ultra-rare indications where traditional randomized trials may not be feasible,” Yang says.
Fast track and breakthrough therapy designations continue to smooth those pathways, and advances in trial design are helping too. “Basket studies and the use of natural history data are making it more practical to study treatments in small patient populations,” says Yang.
Investors, meanwhile, are concentrating their bets on the disease areas and technologies with the clearest path from platform to clinic. “Money is concentrating in rare neurodegeneration, rare oncology, and the enabling platforms—AI target ID, smarter delivery, and repeat-dose AAV—with investors paying up for proximity to clinical data and non-dilutive royalty and debt structures returning for late-stage rare disease assets,” says Hedrick.
Here are 11 companies making their way in the rare disease space.
Sarepta Therapeutics
Sector: Precision genetic medicine for neuromuscular rare diseases
HQ: Cambridge, MA
Year Founded: 1980 (rebranded 2012)
Origin story: Founded as AntiVirals Inc., in 1980 in Corvallis, Oregon, the company spent decades on antiviral work before pivoting to rare genetic disease. A 2012 rebrand to Sarepta Therapeutics formed the company’s focus on Duchenne muscular dystrophy and precision genetic medicine.
Key Leaders: Douglas S. Ingram, CEO; Ian M. Estepan, President and COO; Louise Rodino-Klapac, President, R&D Technical Operations
Number of Employees: ~835
Stage: Publicly traded
Financial Snapshot:The company’s market cap as of July 2026 was $2 billion.
Key Products: Elevidys, a micro-dystrophin gene therapy for Duchenne patients; Exondys 51, Vyondys 53, and Amondys 45, which are exon-skipping RNA drugs for distinct DMD patient subsets; emerging siRNA pipeline targeting DM1, FSHD, Huntington’s disease, idiopathic pulmonary fibrosis, and spinocerebellar ataxia type 2 (SCA2)
Recent Highlights: In May 2026, Sarepta announced its product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of Elevidys net product revenue and $228.6 million of PMO net product revenues.
Ultragenyx Pharmaceutical
Sector: Gene therapy and biologics for rare and ultra-rare genetic diseases
HQ: Novato, CA
Year Founded: 2010
Origin Story: Emil Kakkis, MD, PhD, a physician-scientist who developed the first enzyme replacement therapy for MPS I at BioMarin, founded Ultragenyx to pursue serious rare and ultra-rare genetic diseases.
Key Leaders: Emil D. Kakkis, MD, PhD, CEO & President; Howard Horn, Chief Financial Officer; Eric Crombez, MD, Chief Medical Officer; Erik Harris, Chief Commercial Officer
Number of Employees: ~1,371
Stage: Commercial-stage, publicly traded
Financial Snapshot:The market cap as of July 2026 was $3.331 billion
Key Products: Crysvita, anti-FGF23 antibody for X-linked hypophosphatemia; Dojolvi for long-chain fatty acid oxidation disorders; Evkeeza for homozygous familial hypercholesterolemia; UX111, AAV gene therapy for Sanfilippo syndrome type A; UX701, gene therapy for Wilson disease; GTX-102, antisense oligonucleotide for Angelman syndrome
Recent Highlights: In February 2026, Ultragenyx reported $207 million in total revenue for the fourth quarter 2025 and a projection of 2026 total revenue from current products to be between $730 million to $760 million. The company is poised for up to four new therapy launches over the next two years related to osteogenesis imperfecta and Angelman syndrome.
Intellia Therapeutics
Sector: In vivo CRISPR/Cas9 gene editing for rare genetic diseases
HQ: Cambridge, MA
Year Founded: 2014
Origin Story: Co-founded by Atlas Venture and Caribou Biosciences, Intellia licensed foundational CRISPR/Cas9 technology developed by Nobel laureate Jennifer Doudna from UC Berkeley. The company was built to use lipid nanoparticle-delivered CRISPR to edit genes directly inside the liver.
Key Leaders: John Leonard, MD, PhD, CEO; James Basta, JD, Executive Vice President, General Counsel & Corporate Secretary; David Lebwohl, MD, Executive Vice President & Chief Medical Officer; Birgit Schultes, PhD, , Executive Vice President & Chief Medical Officer
Number Of Employees:~377
Stage: Publicly traded
Financial Snapshot:The market cap as of July 2026 was $1.98 billion.
Key Products: Lonvoguran ziclumeran (lonvo-z), single-dose in vivo CRISPR therapy for hereditary angioedema (HAE); Nex-z (NTLA-2001), in vivo CRISPR therapy for ATTR amyloidosis
Recent Highlights: In June 2026, the company announced positive Phase 3 results for Lonvoguran Ziclumeran (lonvo-z) in patients with hereditary angioedema.
In May 2026, Intellia announced that its cash, cash equivalents, and marketable securities were $517.2 million as of March 31, 2026. Additionally, it stated that as of April 2026, the company executed an underwritten public offering of its common stock for approximately $207 million in gross proceeds.
Beam Therapeutics
Sector: Base editing, precision single-nucleotide gene editing for rare hematologic and genetic diseases
HQ: Cambridge, MA
Year Founded: 2017
Origin Story: Co-founded in 2017 by David Liu, PhD at Harvard University, John Evans, and J. Keith Joung to commercialize Liu’s invention of base editing, a technology that makes precise single-letter changes in DNA without creating double-strand breaks, avoiding the genome instability risks of conventional CRISPR scissors.
Key Leaders: John Evans, CEO; Giuseppe Ciaramella, PhD, President; Amy Simon, MD, Chief Medical Officer; Gopi Shanker, PhD, Chief Scientific Officer
Number Of Employees:~522
Stage: Publicly traded
Financial Snapshot:The market cap was $3.36 billion as of July 2026.
Key Products: Risto-cel (ristoglogene autogetemcel), autologous base-edited cell therapy for severe sickle cell disease; BEAM-302, first clinical program to directly correct a disease-causing mutation in vivo for alpha-1 antitrypsin deficiency (AATD); BEAM-301, in vivo base editing for Glycogen Storage Disease Type Ia (R83C mutation)
Recent Highlights: In June 2026, Beam Therapeutics announced clearance of investigational new drug application for BEAM-304 for the treatment of Phenylketonuria (PKU).
In May 2026, Beam announced the publication of data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease in the April 1 Issue of the New England Journal of Medicine.
BridgeBio Pharma
Sector: Diversified genetic medicine, novel portfolio model for rare genetic diseases
HQ: Palo Alto, CA
Year Founded: 2015
Origin Story: BridgeBio was built around a portfolio theory for biotech pioneered by Neil Kumar, PhD, and co-founder Andrew Lo of MIT’s Sloan School of Management. Their approach was based on the idea that instead of concentrating risk on one drug, assemble a diversified slate of programs across genetic diseases, apply formal NPV-driven decision-making, and let portfolio breadth absorb failures that would destroy a single-asset company.
Key Leaders: Neil Kumar, PhD, Founder & CEO; Thomas Trimarchi, PhD, President & Chief Financial Officer; Andrew Lo, PhD, Co-founder & member of the Board of Directors
Number Of Employees: ~839
Stage: Publicly traded
Financial Snapshot:The market cap was $16.82 billion as of July 2026.
Key Products: Attruby (acoramidis), near-complete TTR stabilizer for ATTR-CM; BBP-418, glycosylated ribitol for LGMD2I/R9; Encaleret, calcilytic for autosomal dominant hypocalcemia type 1 (ADH1); Infigratinib, oral FGFR3 inhibitor for achondroplasia
Recent Highlights: In June 2026, BridgeBio announced publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of oral Infigratinib in children living with achondroplasia. In May 2026, the company announced that the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Ionis Pharmaceuticals
Sector: RNA-targeted antisense oligonucleotide (ASO) therapeutics; neurology and rare disease
HQ: Carlsbad, CA
Year Founded: 1989
Origin Story: Founded in 1989 by Stanley Crooke, MD, PhD, on the premise that targeting RNA, rather than proteins, could unlock diseases once considered undruggable. Crooke spent three decades proving out the antisense oligonucleotide (ASO) concept, producing SPINRAZA and a steadily expanding pipeline of RNA-targeted medicines.
Key Leaders: Brett P. Monia, PhD, CEO; Elizabeth L. Bhatt, Executive Vice President & COO; C. Frank Bennett, PhD, Executive Vice President & Chief Scientific Officer
Number Of Employees: ~1,402
Stage: Publicly traded
Financial Snapshot:The market cap was $9.62 billion as of July 2026.
Key Products: Tryngolza (olezarsen), first and only treatment for familial chylomicronemia syndrome (FCS); Dawnzera (donidalorsen), first RNA-targeted prophylactic therapy for hereditary angioedema (HAE); Zilganersen, ASO for Alexander disease (AxD); Spinraza (nusinersen), treatment for spinal muscular atrophy
Recent Highlights: In February 2026, the company announced that Tryngolza generated $108 million in net product sales in 2025, its first year of launch. It also stated that it exceeded 2025 financial guidance and that its 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients.
Atrium Therapeutics
Sector: RNA therapeutics for rare, life-threatening genetic cardiomyopathies
HQ: San Diego, CA
Year Founded: 2026
Origin Story: Atrium Therapeutics was spun out of Avidity Biosciences in connection with Novartis’s $12 billion acquisition of Avidity, which closed in February 2026. Novartis wanted Avidity’s late-stage neuromuscular RNA franchise but not its earlier-stage precision cardiology programs, so those assets, including two preclinical candidates and a licensing agreement for the validated AOC delivery platform, were carved out into a newly independent, publicly traded company. Atrium launched on February 27, 2026, inheriting Avidity’s existing cardiology partnerships with Eli Lilly and Bristol Myers Squibb.
Key Leaders: Kathleen Gallagher, CEO; Steve Hughes, MD, Chief Medical Officer; Rocio Martin Hoyos, Chief Strategy Officer; Husam Younis, PhD, PharmD, Chief Scientific Officer
Number of Employees: 11-50
Stage: Publicly traded
Financial Snapshot:The market cap was $213 million as of July 2026.
Key Products: ATR-1072, preclinical RNA candidate for PRKAG2 syndrome, a rare genetic cardiomyopathy; ATR-1086, preclinical RNA candidate for phospholamban (PLN) cardiomyopathy, a rare inherited heart condition
Recent Highlights: On February 27, 2026, Atrium launched as an independent, publicly traded company spun out of Avidity Biosciences following Novartis’s acquisition of Avidity. CEO Kathleen Gallagher said Atrium started with a Novartis-validated RNA delivery platform, originally designed to deliver therapies to muscle tissue and now being applied to the heart. The company stated that its two lead candidates, ATR 1072 for PRKAG2 syndrome and ATR 1086 for phospholamban cardiomyopathy, are both in early-stage development, and it aims to file an IND for one in the second half of 2026 and for the other in 2027.
Amicus Therapeutics (Acquired by BioMarin Pharmaceutical)
Sector: Lysosomal storage disorders; enzyme replacement therapy and pharmacological chaperones
HQ: Princeton, NJ
Year Founded: 2002
Origin Story: Founded in 2002, Amicus was galvanized in 2005 when John Crowley became CEO. Two of Crowley’s children were diagnosed with Pompe disease with a life expectancy of just a few years. His mission to save them drove the company’s founding ethos and became the basis of the 2010 film “Extraordinary Measures.” The company’s name, Latin for ‘friend,’ reflects its patient-first identity.
Key Leaders: Bradley Campbell, CEO
Number Of Employees: ~500
Stage: Subsidiary of BioMarin Pharmaceutical
Financial Snapshot: Acquired by BioMarin Pharmaceutical for $4.8B in April 2026
Key Products: Galafold (migalastat), first oral precision therapy for Fabry disease; Pombiliti + Opfolda (cipaglucosidase alfa + miglustat), first two-component therapy for late-onset Pompe disease; DMX-200, licensed Phase 3 program for FSGS (focal segmental glomerulosclerosis)
Recent Highlights: In April 2026, BioMarin acquired Amicus for $4.8B.
Krystal Biotech
Sector: Redosable HSV-1-based gene therapy for rare skin, respiratory, and ocular diseases
HQ: Pittsburgh, PA
Year Founded: 2016
Origin Story: Founded in 2016 by Krish S. Krishnan and Suma M. Krishnan, who had worked together across New River Pharmaceuticals and Intrexon before striking out on their own. Their pioneering insight: the herpes simplex virus-1 (HSV-1), re-engineered and stripped of pathogenic elements, could serve as a safe, repeatedly administrable gene delivery vector, built with in-house CGMP manufacturing from inception.
Key Leaders: Krish S. Krishnan, Chairman, President & CEO; Suma M. Krishnan, President of Research & Development; Kathryn Romano, EVP & Chief Accounting Officer
Number Of Employees: ~300
Stage: Publicly traded
Financial Snapshot:The company’s market cap was $10.78 billion as of July 2026.
Key Products: Vyjuvek (beremagene geperpavec), redosable gene therapy; KB407, inhaled HSV-1 gene therapy for cystic fibrosis; KB408, inhaled HSV-1 gene therapy for alpha-1 antitrypsin deficiency (AATD) lung disease; KB801, for neurotrophic keratitis; KB803 for ocular DEB; KB111 for Hailey-Hailey disease
Recent Highlights: In February 2026, Krystal announced that it generated $389M in 2025 Vyjuvek revenue at a 94% gross margin, and that it aims to treat 10,000+ rare disease patients by the end of 2030.
Entrada Therapeutics
Sector: Intracellular RNA and oligonucleotide delivery for neuromuscular and genetic diseases
HQ: Boston, MA
Year Founded: 2016
Origin Story: Founded around the Endosomal Escape Vehicle (EEV) platform, a proprietary technology designed to ferry oligonucleotides across the endosomal membrane, the major intracellular barrier that renders most RNA-based drugs ineffective in non-liver tissues.
Key Leaders: Dipal Doshi, CEO; Nathan J. Dowden, President & COO; Natarajan Sethuraman, PhD, President of Research and Development
Number Of Employees:~150
Stage: Publicly traded
Financial Snapshot:The company’s market cap was $268 million as of July 2026.
Key Products: ENTR-601-44, an EEV-PMO for DMD exon 44 skipping; ENTR-601-45, an EEV-PMO for DMD exon 45 skipping; VX-670 (formerly ENTR-701), an EEV-PMO for DM1, now partnered with and led by Vertex Pharmaceuticals under a global collaboration; ENTR-801 for Usher syndrome type 2A
Recent Highlights: In February 2026, Entrada announced that it received a positive DMC recommendation to escalate ENTR-601-44 to 12 mg/kg in its DMD exon 44 trial and that multiple clinical readouts across the DMD franchise are expected in 2026.
Rocket Pharmaceuticals
Sector: Ex vivo and in vivo gene therapy for rare blood, cardiac, and metabolic diseases
HQ: Cranbury, NJ
Year Founded: 2015
Origin Story:The company was built by a team with deep roots in hematology gene therapy at leading academic medical centers and the NIH, with an explicit focus on ultra-rare diseases that have no approved treatments.
Key Leaders:Gaurav Shah, MD, CEO; Syed Rizvi, MD, Chief Medical Officer; Jonathan Schwartz, MD, Chief Science & Gene Therapy Officer; Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer
Number Of Employees:~200
Stage: Publicly traded
Financial Snapshot:The company’s market cap was $426 million as of July 2026.
Key Products: RP-L301, an investigational LVV gene therapy for pyruvate kinase deficiency (PKD); RP-A501, an AAV9.LAMP2B gene therapy for Danon disease, a rare X-linked cardiomyopathy; LAD-I gene therapy, an advanced program for leukocyte adhesion deficiency type I, a life-threatening primary immunodeficiency; RP-L102, an LVV gene therapy for Fanconi anemia (FA) complementation groups A and C
Recent Highlights: In June 2026, Rocket announced the closing of sale of rare pediatric disease priority review voucher for $180 Million. In May 2026, the company announced cash equivalents and investments of approximately $322.6 million, including balance as of March 31, 2026, and non-dilutive proceeds from its PRV sale.
